Gary L. Buchschacher

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares et al. · The Lancet Oncology · 2019 · 1.7K citations · Full text

Medicine, Oncology, Metastasis +9

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · NEJM Evidence · 2022 · 394 citations

Medicine, Oncology, Pharmacology +17

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg et al. · The Lancet · 2021 · 329 citations · Full text

Medicine, Oncology, Urology +12

A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity.

Eric O. Freed, Eric Delwart, Gary L. Buchschacher et al. · Proceedings of the National Academy of Sciences · 1992 · 279 citations

Life Sciences, Biochemistry, Molecular Biology +17